Little-Known Chinese Company Shocks Pharma Industry with Breakthrough Drug

Little-Known Chinese Biotech Shakes Up the Industry with Groundbreaking Cancer Drug

China’s DeepSeek Sparks a Wave of Innovation Beyond Big Tech

China’s rise in innovation isn’t limited to technology—it’s quietly transforming the pharmaceutical industry as well. In a groundbreaking development, Akeso, a little-known Chinese biotech company, has delivered a lung cancer drug that outperformed the world’s best-selling medicine, Keytruda by Merck.

A Game-Changing Discovery

In September 2024, clinical trials conducted in China revealed that Akeso’s drug, Ivonescimab, delivered superior results compared to Keytruda, which has amassed over $130 billion in global sales.

Clinical Trial Results:

• Ivonescimab: Patients went 11.1 months before tumor progression.
• Keytruda: Patients saw progression in just 5.8 months.

The results, unveiled at the World Conference on Lung Cancer, marked a historic moment for Chinese biotech—but at the time, it went largely unnoticed outside the industry.

Stock Surge & Global Attention

That changed when DeepSeek, another Chinese firm, made headlines with its own medical breakthroughs, drawing global attention to China’s growing pharmaceutical power.

In early September, shares of Summit Therapeutics, Akeso’s U.S. partner, more than doubled, reaching record highs. The California-based company had secured the exclusive rights to commercialize Ivonescimab in North America and Europe, making it a major player in the global market.

“We believe the Chinese biotech industry will play an important role globally,” said Michelle Xia, CEO of Akeso, in an interview with BiotechTV.

Akeso also expressed its excitement in a statement to CNN, highlighting that its innovation comes from a deep understanding of disease biology and protein engineering, as well as China’s fast-paced development process and highly skilled talent pool.

China’s Biotech Boom: From Copycats to Innovators

For decades, China’s pharmaceutical industry focused on producing “me-too” drugs, essentially low-cost replicas of existing medications. That began to change over the last 10 years, with Chinese biotech firms now producing cutting-edge medications that compete with Western pharmaceutical giants.

Major Licensing Deals with Western Firms:

• AstraZeneca & CSPC Pharmaceutical Group – $1.92 billion deal for cardiovascular medication.
• Merck & Hansoh Pharmaceutical – $2 billion partnership for an experimental weight-loss drug.

Experts say the shift is undeniable.

“People knew China’s biotech industry was growing fast, but few saw it as a real threat to top U.S. innovators,” said Rebecca Liang, pharmaceuticals analyst at AB Bernstein. “Now, with next-generation drugs like Ivonescimab, that threat is getting real.”

China’s Rise as a Global Innovation Hub

According to HSBC Qianhai Securities, China has rapidly become an innovation hotspot for biotech:

Key Industry Growth Stats:

• Licensing deals: 46 in 2017 → 200+ in 2023
• Total deal value: $4 billion (2017) → $57 billion (2023)
• Large pharmaceutical transactions (above $50M) grew 30% in 2024 compared to 2023.

“Chinese biotech firms’ research capabilities and efficiency are catching up fast,” said Cui Cui, Managing Director of Healthcare Research at Jefferies. “Government support, foreign investment, and local talent are all fueling this growth.”

Doubts at Home: Can Chinese Drugs Win Over Local Patients?

While Akeso’s drug is making waves globally, many Chinese citizens remain skeptical about domestic pharmaceuticals.

Concerns over generic drug quality recently sparked a public outcry, leading to an official investigation into China’s pharmaceutical industry. The country’s health regulator later defended the safety of domestic medications, but doubts persist.

Public Opinion in China:

• Gu Zhihao, a Beijing resident: “To be honest, I prefer the more expensive imported medicine. After all, you get what you pay for.”
• US Investors & FDA Concerns: The FDA has previously rejected drugs developed in China, citing trial methodology concerns.

What’s Next for Akeso & Ivonescimab?

While China’s drug regulator has approved Ivonescimab for some lung cancer patients, it will take years before it reaches the U.S. market.

Upcoming Global Trial (2025): A new international clinical trial is planned, which could validate Ivonescimab’s efficacy on a global scale. If successful, it would cement China’s role as a biotech leader and challenge Western dominance in cancer treatment.

Conclusion: A New Era in Global Pharma

China’s biotech industry is no longer just catching up—it’s now a serious contender in global drug development. If companies like Akeso and DeepSeek continue delivering breakthrough treatments at lower costs, the entire pharmaceutical landscape could shift dramatically.

Is the world ready for Chinese-made, best-in-class medicines? The success of Ivonescimab may be the first major test.

Source